Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial

doi:10.3748/wjg.v29.i24.3871

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3788)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

2101

Figures (1-3)

360

Tables (1-3)

280

Sum=2868

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

160

Download

591

Sum=751

Jun 28, 2023 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jun 28, 2023; 29(24): 3871-3882
Published online Jun 28, 2023. doi: 10.3748/wjg.v29.i24.3871

Full Size Figure Download Figure

Figure 1 Kaplan-Meier analysis of median progression-free survival according to the response evaluation criteria in solid tumors version 1. 1. mPFS: Median progression-free survival; SBRT: Stereotactic body radiotherapy.

Citation: Chen YX, Yang P, Du SS, Zhuang Y, Huang C, Hu Y, Zhu WC, Yu YY, Liu TS, Zeng ZC. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial. World J Gastroenterol 2023; 29(24): 3871-3882
URL: https://www.wjgnet.com/1007-9327/full/v29/i24/3871.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i24.3871